Chapter 18: The Pituitary Gland

Welcome to Last Minute Lecture.

This free chapter overview is designed to help students review and understand key concepts.

These summaries supplement not replaced the original textbook and may not be redistributed or resold.

For complete coverage, always consult the official text.

Welcome to the Deep Dive.

Our mission today is to take a stack of highly complex physiological sources, specifically Chapter 18 from Gannon's Review of Medical Physiology, and condense the incredible detail of the pituitary gland into actionable integrated knowledge.

We're diving deep into the central command unit of the endocrine system.

The pituitary is often called the master gland and, you know, for good reason.

It coordinates this massive cascade of downstream endocrine processes.

But as we'll see, it's not really a single entity.

Not at all.

It's fundamentally two separate organs that just happen to be sharing the same space in the skull.

Absolutely.

And the goal for you, the learner, is to walk away with a crystal clear map of this gland.

It's dual origins, the specialized cells that power it, and the complex feedback mechanisms, particularly for growth hormone, prolactin, and the gonadotropins.

Right.

We're going to focus on those three.

The text saves the really deep dives on ACTH and TSH for other chapters, and we've already covered basopressin and oxytocin.

So this chapter is really foundational.

It sets up how this central coordinator works.

Exactly.

How it gets signals from the hypothalamus and how it manages these huge physiological states like growth, metabolism, reproduction.

We're really going to focus on the structure, the regulation, and some of the surprising dual actions that make hormones like GH so powerful.

Perfect.

Let's start with the basics then.

The anatomy.

Okay.

The pituitary, or the hypothesis, it sits protected in the cell tursica, that little bony cladal in the sphenoid bone, and it's tethered right up against the hypothalamus.

But its function, really it all comes down to its origin story.

You really have to think of it as a merger of two totally distinct things.

They look like one gland, but they couldn't be more different.

So let's start with the posterior pituitary, the neurohypophysis.

Right.

So this is the simpler lobe, functionally speaking.

It's a direct downward extension of neural tissue from the hypothalamus.

It's basically an outpost for the brain.

An outpost that just stores and releases hormones, but doesn't actually make them.

Exactly.

The posterior lobe is mostly just the terminal endings of axons.

The cell bodies are way up in the supraoptic and paraventricular nuclei of the hypothalamus.

So vasopressin and oxytocin are made up there, packaged up, and then just shipped down the axons for storage.

Yep.

Shipped down and stored until a neural signal tells them to release.

And to support these nerve endings, the lobe has these specialized glial cells called pituitocytes.

And pituitocytes are what?

Kind of like astrocytes providing support?

Precisely.

They're modified astrocytes.

Their whole job is to support that storage and release process.

So the posterior pituitary is 100 % neural in its makeup and its control.

Okay.

Now contrast that with the anterior pituitary, the adenohypophysis.

Totally different world.

This part is made of classic endocrine cells, true secretory cells.

And embryologically, it comes from an upward imagination of the pharynx.

It's a little structure called the Rathke pouch.

So we have a piece of the brain fused to a piece that started out as the roof of the mouth.

That is a bizarre meeting point for the body's main command center.

It is, but it explains everything.

It explains why their communication pathways with the hypothalamus are so radically different.

And what about the intermediate lobe?

Well, in a lot of other animals, it's a distinct functional lobe.

In adult humans, it's pretty much rudimentary.

The cells that would have formed it, cells that process a molecule called POMC, they just get integrated right into the anterior lobe.

That integration is what lets the anterior lobe be such a diverse factory.

So let's look inside that factory.

For this one tiny organ to control the thyroid, the adrenals, the gonads, metabolism, it must have specialized assembly lines.

The diversity is remarkable.

And, you know, their proportions tell you a lot about what the gland is focused on.

By far the most abundant cells are the somatotropes.

Making up about half the population.

About 50%, yeah.

And they secrete growth hormone, or GH.

This huge percentage really underlines GH's constant wide -ranging metabolic and anabolic influence.

It's not just for kids growing up.

Half the cellular real estate is just for GH production.

That's a pretty compelling piece of evidence for its importance.

It really is.

The other major players are the lactotropes.

They secrete prolactin, that's maybe 10 to 30%.

The gonadotropes, which secrete both FSH and LH, they're about 20%.

And the rest?

The rest of the corticotropes for ACTH, about 10%.

And the pyrotropes for TSH, only about 5%.

Okay, now connecting the hypothalamus, the commander to this factory floor, requires a very specialized plumbing system.

Why is that portal -hypophytidal system so critical?

It's everything.

Because the anterior pituitary isn't directly wired to the hypothalamus with nerves, it relies on this unique vascular link.

All the hypothalamic releasing and inhibiting factors, GHRH, somatostatin, GNRH, they get released into capillaries in the median eminence.

And those capillaries drain right into the portal vessels.

Right, which then carry that blood directly and immediately to the capillaries that are bathing the anterior pituitary cells.

So instead of dumping these command signals into the general circulation where they'd get diluted and chewed up, this system delivers a high -concentration message right to the target's doorstep.

It's like a dedicated high -speed delivery service.

Maximum efficiency.

And rapid, sensitive control.

The other cool structural insight involves the glycoprotein hormones,

FSH, LH, and TSH.

They're all very similar.

And they share that common alpha subunit.

Exactly.

Molecular economy at its best.

They all share a common alpha subunit, product of a single gene.

The hormone's unique identity, its specific function, that's all conferred by its unique beta subunit, which comes from a different gene.

So the body just needs to make the specific beta chain to change its output.

You got it.

And before we move on, we should mention that this gland isn't static.

It has a surprising amount of cellular plasticity.

Right, the folliculostalate cells and the stem cells.

It's a crucial modern insight.

The gland has these non -secretory folliculostalate cells that produce local paracrine factors to regulate the secretory cells.

But more importantly, there seems to be a small population of pluripotent stem cells that hang around in the adult gland.

Which lets the pituitary adjust its priorities.

Precisely.

It can dynamically change the relative proportion of its five secretory cell types based on what the body needs.

Think about pregnancy, right?

You suddenly need massive amounts of prolactin.

The proportion of lactotropes just skyrockets to meet that demand, all thanks to this plasticity.

Okay, let's turn our attention to the propial melanocortin family.

POMC.

It's this single giant precursor protein that gets sliced and diced into a whole bunch of different active hormones.

It sounds like nature's most complex molecular Swiss army knife.

It really is.

There's massive precursors made in the corticotropes, but also all over the place.

Hypothalamus, lungs, GI tract, placenta.

But the core lesson here is that the final hormone you get is entirely determined by the processing enzymes that are available in that specific cell.

Location dictates destiny.

Perfect way to put it.

So how does that cleavage pathway differ between, say, the anterior pituitary and the intermediate lobe cells?

Right.

In the corticotropes of the anterior lobe, the main products are ACTH, a greenocorticotropic hormone, and another piece called beta -lipotropin, or beta -LPH.

You get a tiny bit of beta -endorphin too.

This is the pathway that's optimized for the adrenal stress response.

And if you take that same POMC protein and process it in the cells that are equivalent to the intermediate lobe in humans...

The enzymes there are more aggressive.

They cut the molecule up even further.

ACTH gets hydrolyzed again, giving you something called CLIP.

The beta -LPH gets broken down into gamma -LPH.

But most importantly, this secondary processing pathway generates and secretes much, much more beta -endorphin.

And beta -endorphin is the key takeaway there.

It's an opioid peptide, one of the body's natural painkillers.

Absolutely.

It's an opioid peptide.

It actually contains the met and keflin sequence right at its end terminal end.

And while we still don't really know what CLIP and gamma -LPH do in humans, beta -endorphin is central to pain modulation and emotional regulation.

Now, the text says the melanotropins alpha and beta -MSH are technically formed here, but they're not really secreted in adult humans.

Right.

And that fact that we don't secrete MSH in bulk leads to one of the most surprising things in human physiology,

how we control skin pigmentation.

So lower vertebrates use MSH for camouflage.

Since we don't really use MSH, how does our body manage skin color?

This is where molecular evolution created a fascinating workaround.

So mammals have melanocytes, not those mobile melanophores you see in fish.

And these melanocytes express a receptor called the melanotropin -1 receptor.

Since we don't have a lot of dedicated MSH floating around,

the structurally similar ACTH just binds to these receptors instead.

Wait, wait.

So ACTH, the hormone designed to signal the adrenals to make cortisol moonlights as our main skin darkening hormone.

That's incredible molecular multitasking.

It is.

And it means any condition that drives up ACTH will by necessity drive up pigmentation.

And that is a powerful clinical diagnostic tool.

The classic example is the hyperpigmentation you see in primary adrenal insufficiency.

Like Addison disease.

Exactly.

Let's map that out for a second.

In primary adrenal insufficiency, the adrenal gland itself fails.

So cortisol is low.

The pituitary senses this lack of negative feedback and just cranks out ACTH, trying desperately to stimulate the failed gland.

And all that excess ACTH spills over onto the melanotropin receptors.

Exactly.

Causing that diffuse darkening of the skin and nukes membranes.

And the physiological insight here is huge.

If a patient comes in with adrenal insufficiency and hyperpigmentation, you immediately rule out a secondary cause like a pituitary or hypothalamic problem.

Because if the problem started upstream, the ACTH levels would be low, not high.

You'd have low ACTH and therefore no hyperpigmentation.

That's a textbook signpost.

And on the flip side, a lack of pituitary function leads to the opposite.

Correct.

Pallor or an abnormal paleness is a hallmark of hypopituitarism.

You see it in high pituitary dwarfs, for example.

It's due to the lack of ACTH and other MSH active hormones that are needed to stimulate normal melanin production.

It's important to separate these pituitary driven issues from problems in the skin itself.

Absolutely.

You have to distinguish central signaling from peripheral machinery defects.

So albinism is a total failure to synthesize melanin because of genetic defects in the enzymes.

The ACTH signal is fine, but the factory can't make the product.

And pi -baldism.

That's patchy.

It's from a congenital defect where the pigment cell precursors don't migrate properly during development.

And then you have vitiligo, which is a patchy loss of pigment that develops later in life, usually from an autoimmune attack that just destroys the melanocytes.

And in all those cases, the pituitary adrenal axis is working just fine.

Typically, yes.

The defect is localized right in the pigment cell system.

Let's transition now to the most abundant hormone from the anterior pituitary, growth hormone or somatotropin.

It's obviously fundamental to postnatal growth, but the sources really emphasize its species specificity.

That specificity is key.

Human GH is encoded by the HGHN gene in the pituitary.

And unlike a lot of other hormones like thyroid hormone or the structures conserved across species, GH has to be from the same species to be active.

So bovine GH doesn't work in humans.

Not at all.

And that's why we need recombinant human GH made from that HGHN gene for treating children with GH deficiency.

There are also related genes, HGHV and HCS, which are mostly expressed by the placenta during pregnancy.

It just shows the close family relationship between GH and the hormones that support fetal growth.

Okay.

So once GH is secreted, it has a pretty short half -life, but the body has a system to manage the huge swings in its release, right?

How does it maintain a stable reservoir?

Yeah, the half -life is very short, somewhere between six and 20 minutes.

But about half of the circulating GH is bound to a specific plasma protein.

And here's where it gets really clever.

This binding protein isn't just some random carrier.

It's a large fragment of the growth hormone receptor itself.

You mean it's been cleaved off the cell surface and just floating in the blood?

That's exactly what it is.

The extracellular domain of the receptor gets shed into circulation.

So the body uses pieces of the target to act as a signal.

Precisely.

This bound state creates this crucial stable reservoir that smooths out the massive pulsatile boosts of GH secretion.

And what's more, the concentration of this binding protein in the plasma is a useful clinical tool.

It gives you an index of GH sensitivity, because it reflects how many functional GH receptors are available in the tissues.

Speaking of pulses, GH secretion is wildly erratic.

It's pulsatile, it's diurnal, it peaks in and then declines.

What's controlling all that fluctuation?

The hypothalamic control is this beautifully orchestrated tug of war between stimulation and inhibition.

You have three main players.

First, the gas pedal, GHRH or growth hormone releasing hormone.

Second, the break,

somatostatin or SS, which is inhibitory.

So GH release at any given moment is the net result of GHRH and somatostatin acting on the somatotropes.

And the third player is the interesting one, Grelin.

Grelin adds a fascinating layer.

It's made in the hypothalamus, sure, but its main source is the stomach.

And it's a powerful GH secret gog.

Wait, so the stomach is directly telling the brain to release a growth factor.

That fundamentally changes how we think about hunger signals.

It's not just about getting energy, it's about signaling the entire anabolic system to get ready.

It totally emphasizes how integrated energy management is.

Now, this whole axis is managed by a really sophisticated two -tiered negative feedback system.

This is critical to map out.

GH itself acts on the hypothalamus to antagonize GHRH release.

So that's step one.

And step two involves the downstream product.

Correct.

The key feedback signal comes from the main mediator, IGFI.

GH tells the liver and other tissues to make IGFI.

IGFI then provides dual inhibition.

It acts directly on the anterior pituitary to inhibit GH secretion and it acts on the hypothalamus to stimulate the secretion of somatostatin, the break.

It's a double whammy to make sure the system doesn't run out of control.

That tracks a true system of checks and balances.

Now, let's look at what stimulates release.

The text organizes these really well and it seems like anything that signals stress or energy crisis just ramps up GH.

That is the unifying theme.

The big stimuli are things that signal a drop in cellular energy.

Hypoglycemia, fasting, starvation,

intense exercise, psychological stress.

Also, a high protein meal or an infusion of amino acids like arginine will stimulate GH release.

Right.

The body sees building blocks are available and calls for the foreman.

Exactly.

And then there's sleep.

The connection to sleep is always striking.

The largest pulsatile bursts of GH happen during sleep,

specifically in the deepest stages of non -REM sleep.

And interestingly, it's inhibited during REM sleep.

If you deprive someone of REM sleep, GH secretion actually increases, which suggests some kind of compensating mechanism linking rest, repair, and growth.

Let's revisit that classic experiment that shows GH is sensitive to intracellular energy status, not just blood sugar.

This is a high yield concept.

If you give someone a glucose infusion, plasma GH drops.

The body is satiated.

But if you give them two deoxyglucose, this compound gets into the cell, but it can't be used for energy.

It blocks the first step of glycolysis.

So the cell thinks it's starving, even with plenty of glucose around.

Right.

The cell registers an intracellular energy deficit, and the response is a huge surge in GH secretion.

This experiment proves the system is regulated by signals about the functional availability of fuel, not just the concentration of fuel in the blood.

Okay.

That clarifies the upstream control.

Before we get to its actions, how does GH actually signal inside the cell?

It acts via the growth hormone receptor, or GHR, which is part of the cytokine receptor superfamily.

GH has two distinct binding sites.

When it binds to one receptor, its second site immediately grabs another nearby receptor, causing them to pair up.

It causes homodimerization.

So it takes two receptors to Tango, and GH is the matchmaker.

Exactly.

And that dimerization is the mandatory first step for activation.

Once they're linked, they activate intracellular signaling.

The most crucial pathway here is the JK2 stat pathway.

Okay.

Write that down.

So the dimerized receptor is like a switchboard.

When it's flipped on, it activates a tyrosine kinase called Janus kinase 2, or JK2, which is hanging out just inside the cell, attacked the receptor.

JK2 is the factory manager.

Precisely.

JK2 then phosphorylates a set of cytoplasmic transcription factors known as stats.

Once the stats are phosphorylated, they detach, they move into the nucleus, and they bind directly to DNA to activate specific genes for things like protein synthesis or cell division.

It's a very rapid, direct way to get a message from the cell surface right to the genome.

Now we get to the duality of growth hormone.

It has its own direct metabolic effects, and then these indirect effects on growth mediated by the smetomidins.

Let's start with the direct actions.

GH is a metabolic switcher.

It's like a triage commander during stress or fasting.

In terms of protein and electrolytes, it's highly protein anabolic.

It creates a positive nitrogen and phosphorus balance.

Meaning it's driving the building of tissue.

Right.

It's increasing lean body mass, decreasing body fat.

It's so anabolic that it increases calcium absorption from the gut and reduces sodium and potassium excretion by the kidneys because those minerals are being diverted into new growing tissue.

And this all comes at the cost of carbohydrate tolerance, right?

The diabetogenic effect.

It does.

GH is profoundly diabetogenic.

It acts as a strong anti -insulin agent in muscle, reducing glucose uptake.

At the same time, it increases glucose output from the liver.

GH is basically telling the body glucose is for the brain, everybody else hands off.

And since it's saving glucose, it has to provide another fuel source.

This is where its role as a fat catalyzer comes in.

GH is powerfully ketogenic.

It promotes lipolysis, cranking up the levels of circulating free fatty acids or FFAs.

So the FFAs become the main fuel for the rest of the body.

They become the primary energy source during fasting or stress.

So the triage is burn fat for general energy, save glucose for the brain, and use every other resource to build protein.

That's a perfect summary of its survival role.

Now for the indirect actions, the actual growth promotion.

This led to the discovery of the semitomedins.

Yeah, that journey started when researchers realized GH's effect on cartilage wasn't direct.

It needed some factor in the serum that stimulated the incorporation of sulfate.

So they called it sulfation factor.

Which was later renamed semitomic.

Right.

And eventually they isolated the two main types in humans,

IGFIY, which is also known as semitomedin C, and IGF2.

They're called insulin -like growth factors for a reason.

How close are they to insulin?

Structurally, very similar to pro -insulin.

And the IGFI receptor is remarkably similar to the insulin receptor.

They use very similar tyrosine kinase signaling pathways.

Functionally, what's the difference between IGFI and IGF2?

IGFI is the main growth mediator after birth.

Its secretion is highly GH -dependent, and its plasma levels shoot up during puberty, which correlates perfectly with that growth spurt.

IGF2, on the other hand, is largely GH -independent.

Its main job is during fetal development.

So IGFI is for postnatal growth.

IGF2 is for prenatal growth.

For the most part, yes.

In adults, IGF2 expression is mostly restricted to the brain.

And if IGFI is the critical effector, why doesn't it just get metabolized instantly?

Because of binding proteins.

Both IGFI and IGF2 are tightly bound to plasma proteins.

This protects them.

And it massively prolongs their half -life in the circulation.

We're talking hours for IGFI, compared to minutes for GH.

This stability allows them to act as a sustained growth signal.

So GH is the pulse, but IGFI is the stable signal.

Let's go back to the big question.

Which hormone actually causes growth?

Is it GH directly or IGFI indirectly?

The current thinking is that it's a beautiful cooperative model.

GH definitely has its own direct metabolic roles.

But for skeletal growth, the roles are sequential.

First, GH acts on the growth plate cartilage on the stem cells there.

And it basically converts them into cells that are now highly responsive to IGFI.

So GH primes the tissue.

It primes the orchestra.

Then the locally produced IGFI and the circulating IGFI act as the musician who plays the actual growth notes.

They stimulate the cell division and protein synthesis that leads to growth.

And we know this because… Because if you infuse IGFI alone into a hypophysectomized rat, you can restore bone and body growth.

That experiment confirms that IGFI is the indispensable direct promoter of the growth phase itself.

They work together, but IGFI is the one doing the heavy lifting for growth.

The sources are great at emphasizing that growth is never simple.

It's complex, it's genetic, you need good nutrition, and a whole symphony of hormones beyond just the GH -IGFI axis.

Let's map out the human growth timeline.

Human growth really has two big accelerations.

The first is in infancy.

It's a really rapid growth period, partly a continuation of fetal growth.

And it's driven primarily by GH and thyroid hormones.

And the text points out that this growth isn't smooth, it's salsatory.

Right, it's episodic.

It happens in these little jumps of half to two and a half centimeters over a few days, separated by weeks of no measurable change.

It's pretty amazing.

So what drives the second big spurt?

That's puberty.

And this is the result of a powerful hormonal team.

GH, androgens, and estrogens.

The sex hormones actually induce more GH secretion and make the tissues more responsive to it.

So they massively amplify the GH -IGFI axis to get that maximum growth velocity.

But those same sex hormones are what ultimately stop growth.

That's the paradox of puberty.

It's the ultimate limiter.

Estrogens are the final growth terminators because they cause epiphyseal closure.

They cause the growth plates to fuse with the shafts of the long bones.

Once that cartilage hardens, linear growth is over.

Forever.

Which explains why kids with precocious puberty can end up shorter.

They start their spurt early, but they also finish early.

Exactly.

And the opposite scenario confirms it.

Men who are castrated before puberty because they have very low lifetime estrogen exposure, their epiphysis stay open longer.

So they keep growing past the normal age and often end up taller, but with disproportionately long limbs.

Let's pull in the other key hormones, starting with thyroid hormone.

Thyroid hormones are permissive to GH action.

They potentiate the effects of the somatomedins.

This is so critical clinically.

Severe congenital hypothyroidism leads to what was called cretinism.

These individuals fail to grow, but they also keep their infantile features and body proportions.

And the major inhibitory hormone.

Glucocorticoids like cortisol.

At high doses, they are potent inhibitors of growth.

They're catabolic, they're anti -anabolic, they just shut it all down.

Okay, now for the pathological extremes.

Let's start with GH overproduction.

The clinical picture is completely different depending on when it happens.

That's the hinge point.

If you get GH hypersecretion before the epiphysis closed during childhood, you get gigantism.

Just extraordinary, relatively proportional height.

And if it happens after the growth plates are closed?

Then you get acromegaly.

Linear growth is impossible, but bone can still grow in width and thickness.

So patients develop these dramatically enlarged hands and feet.

A protruding brow and jaw, soft tissue swelling, and enlarged internal organs.

It's an insidious progressive distortion.

How do we treat these tumors?

The approach is multi -pronged.

You can use some metastatin analogs to inhibit GH secretion.

You can try to surgically remove the tumor.

And there are even GH receptor antagonists that can block the hormone from acting on its targets.

Okay, let's flip to the other side.

GH underproduction or insensitivity.

There are a few different ways to get dwarfism.

Right.

It could be GHRH deficiency, GH deficiency, or a problem with IGFI.

The most telling example is learned dwarfism or GH insensitivity.

These patients have normal or even high levels of GH, but they have loss of function mutations in the GH receptor.

The hormone can't signal.

So they can't make IGFI.

Exactly.

They have markedly reduced plasma IGFI.

And this condition really proves, powerfully, that IGFI is the critical final effector of grief.

And how do we tell the different types of dwarfs apart clinically?

Well, as we said, hypothyroid dwarfs keep their instantile proportions.

Pan -hypopatuitary dwarfs, the ones who lack all the pituitary hormones, they're usually proportionate for their age.

But because they lack FSH and LH, they never go through puberty.

So they look juvenile, even as adults.

And what's the story with African pygmies?

That's an interesting physiological puzzle.

They have normal GH secretion.

Their short stature seems to be linked to a failure of their plasma IGFI levels to increase normally during puberty.

It's not a GH problem.

It's a failure in the puberty amplification of the IGFI signal.

It's astonishing how many different points along that one axis can be interrupted to produce such profound outcomes.

It really highlights that growth is not a guarantee.

It requires the perfect timing and function of every single molecular piece in that chain.

Let's shift gears to the reproductive axis.

Let's start with the gonadotropins, FSH and LH.

We said earlier they're glycoproteins.

Why does that matter functionally?

The fact that they're glycoproteins means they have all these carbohydrate residues attached.

Yeah.

And that structure is crucial because it dramatically slows down their metabolism.

So they last longer in the blood.

Much longer.

Compared to GH with a half -life of maybe 20 minutes, FSH has a half -life of around 170 minutes and LH is around 60.

This allows them to act over longer periods, which is essential for coordinating something as complex as the menstrual cycle.

And their actions are distinct even though they come from the same cell type.

In males, FSH acts on sertoli cells to support sperm production.

LH acts on lay -dig cells to stimulate testosterone synthesis.

And in females?

In females, FSH kicks off the early growth of ovarian follicles.

LH is responsible for the final maturation of the follicle, for triggering estrogen secretion and, most critically, for causing ovulation.

It also gets the corpus luteum started.

The text mentions some fascinating clinical points about the FSH receptor.

Yeah, the receptor is very sensitive.

The loss of function mutation causes hypogonadism.

But a gain of function mutation can cause something called spontaneous ovarian hyperstimulation syndrome.

Which sounds bad.

It's very bad.

Massive follicular stimulation.

Huge increase in vascular permeability.

And potentially systemic shock.

Just shows how finely tuned these receptors have to be to work safely.

Now for prolactin.

Structurally, it's related to GH.

But its control mechanism is totally unique among the anterior pituitary hormones.

This is a point that always needs to be emphasized.

It is the defining regulatory difference.

Prolactin secretion is under tonic inhibition by the hypothalamus.

Meaning the hypothalamus is constantly holding the brakes on.

Constantly.

And the primary inhibitory signal is the neurotransmitter dopamine.

So dopamine is often called the prolactin inhibiting hormone.

So if you cut the connection to the hypothalamus, prolactin levels shoot up while everything else goes down.

Exactly.

If you sever the pituitary stalk, all the other anterior to pituitary hormone levels plummet.

But prolactin secretion dramatically increases because you've removed that constant dopamine brake.

It's a crucial physiological fact.

What are the normal stimuli that can override this constant no signal from dopamine?

A lot of things can.

Secretion is increased by sleep, exercise, stress, pregnancy, and the most potent physiological stimulus is nipple stimulation or suckling.

Hormones like TRH and estrogens also increase prolactin secretion.

And prolactin has its own clever negative feedback loop.

It does.

It uses its own inhibitor.

Prolactin actually facilitates the secretion of dopamine in the median eminence.

So by increasing the release of the thing that inhibits it, prolactin neatly controls its own levels.

Which is why dopamine -related drugs have such profound effects on prolactin?

Precisely.

Dopamine agonists like bromocryptine, they powerfully decrease prolactin secretion.

On the other hand, dopamine antagonists like the anti -psychotic chlorpromazine, they block those receptors and can cause a big increase in prolactin, sometimes even leading to pathological lactation or galacturia.

And finally, its main job.

Its primary function, after the breast has been primed by estrogen and progesterone, is to cause milk secretion.

But its key reproductive role is inhibitory.

High levels of prolactin suppress gonadotropin secretion.

This is the mechanism that prevents ovulation in women who are actively and intensely nursing.

In men, high prolactin levels from a tumor can cause erectile dysfunction.

We've established that pituitary is the central command center.

So when it fails, hypopituitarism, the consequences are, well, catastrophic.

It's a predictable systemic collapse.

You lose ACTH, so the adrenal cortex atrophies.

This means a huge drop in glucocorticoids and adrenal sex hormones.

And critically, these patients are acutely intolerant of distress because they can't mount that cortisol response they need to survive.

Do they suffer from the same severe salt loss as patients with primary adrenal failure?

That is a crucial distinction.

And typically, no.

Basal aldosterone secretion, which is regulated mainly by the renin -angiotensin system, stays relatively normal at first.

So salt loss isn't the initial crisis.

The main danger is the glucocorticoid deficiency.

And the loss of TSH in the gonadotropins.

Loss of TSH leads to secondary hypothyroidism.

So poor cold tolerance, low energy.

Loss of SSH and LH causes gonadotrophy, so infertility.

Loss of secondary sex characteristics.

And tying back to the beginning, the lack of ACTH and MSH active hormones causes that characteristic pallor.

Let's talk about the critical metabolic consequences.

Hypophysectomized patients are famous for being highly sensitive to insulin.

Why is that?

They are exquisitely sensitive to insulin and very prone to life -threatening hypoglycemia, especially when they're fasting.

And it's not because they have too much insulin.

It's because they lack the counter -regulatory hormones.

They lose the anti -insulin effect of GH.

And they lose the gluconeogenic support from glucocorticoids.

Without those two main breaks, insulin just runs the show and it becomes incredibly hard for the body to maintain blood glucose.

This brings us to the water metabolism paradox, a truly fascinating physiological compensation.

If you remove the whole pituitary, why don't patients get permanent severe diabetes insipidus?

This is a textbook example of systemic interaction.

So selective damage to the posterior pituitary does cause diabetes insipidus.

But taking out the whole thing often causes only transient polyuria or sometimes done at all.

And the explanation is?

It's elegant.

The loss of ACTH, TSH, and GH dramatically decreases the overall metabolic rate.

And crucially, it dramatically decreases protein catabolism.

Fewer broken down proteins.

Why does that matter for the kidney?

When you break down proteins, you produce urea and other waste products that act as osmotically active particles.

The kidney has to filter these and excrete them and water follows them.

So by removing GH, ACTH, and TSH,

dramatically reduce the load of these osmotic particles that the kidney has to process.

A reduced osmotic load.

Right.

And that means the kidney needs significantly less water to flush the system.

So even without enough vasopressin, the low osmotic load naturally leads to a smaller urine volume.

It effectively cancels out the polyuria.

So the anterior pituitary hormones normally contribute to the body's diuretic state by forcing the kidney to deal with all this metabolic waste.

That is a brilliant piece of physiological triage.

It confirms that you always have to consider the net effect of all the hormones that are lost.

Finally, what are the main causes of pituitary failure in humans?

The most common causes are tumors of the anterior pituitary, adenomas.

You also see supercellar cysts, which are often remnants of Rathke's pouch.

But one of the most specific and severe causes is Sheehan syndrome.

Postpartum necrosis.

Tell us about that pathology.

It's an infarction tissue death from lack of blood supply of the pituitary.

That follows severe systemic shock, usually a massive postpartum hemorrhage.

The critical factor is that during pregnancy, the pituitary gland gets much bigger.

But its blood supply, which passes down through this rigid bony structure, can't handle the vasoconstriction that comes with shock.

The enlarged, compromised gland is just highly susceptible to ischemia, leading to irreversible tissue death and panhypopituitarism.

We have covered a huge amount of material today, from the dual embryonic origins of the pituitary, to the catastrophic systemic results of its failure.

To recap the highest yield principles, the anterior pituitary is this complex factory of specialized cells controlled by hypothalamic portal factors.

And growth hormone and its mediator, IGFI, drive postnatal growth through these dual actions.

GH managing metabolism and priming the tissue, and IGFI executing the actual growth.

And remember that the failure of the central command leads to a multi -system collapse, characterized by stress intolerance, high insulin sensitivity leading to hypoglycemia, and those fascinating metabolic and water balance paradoxes that just show how interconnected all these tropic hormones really are.

So we'll end with this provocative thought.

The central endocrine command is built from two fundamentally different evolutionary components, neural tissue and pharyngeal tissue.

Yet they're united by this unique vascular system to regulate nearly every aspect of human life.

So considering that dual origin, what does this integrated yet fragile structure teach us about the inherent trade -offs between evolutionary efficiency and system vulnerability?

It's a structure that works perfectly until one tiny piece breaks, and then the whole system can collapse.

That integration is definitely a concept worth mulling over.

A compelling question indeed.

Thank you for joining us for this deep dive into your central command.